Combining Immunotherapies

May 13, 2014
Jedd D. Wolchok, MD, PhD

Jedd D. Wolchok, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses ongoing research regarding combinations of immunotherapies.

Clinical Pearls

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center, discusses ongoing research regarding combinations of immunotherapies.

  • Aphase III study led by MSKaims to compare nivolumab, ipilimumab, and the combination of the drugs in newly diagnosed patients with advanced melanoma.
  • There remains a need to determine the benefits of concurrent combination therapies versus sequenced therapies.